Review Article

PPAR-α Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration

Marisol del V Cano and Peter L. Gehlbach
The Wilmer Ophthalmological Institute, School of Medicine, Johns Hopkins University, Baltimore, MD 21287-9278, USA
Correspondence should be addressed to Peter L. Gehlbach, pgelbach@jhmi.edu
Received 1 November 2007; Revised 24 January 2008; Accepted 19 February 2008
Recommended by Suofu Qin

The peroxisome proliferator-activated receptors (PPAR's) are members of the steroid/thyroid nuclear receptor, superfamily of transcription factors. There are currently three known PPAR subtypes, α, β, and γ. The PPARs are now recognized participants in a number of biological pathways some of which are implicated in the pathogenesis of age-related macular degeneration (AMD). These include immune modulation, lipid regulation, and oxidant/antioxidant pathways important to the onset and progression of “dry” AMD, and vascular endothelial growth factor (VEGF) mediated pathways that stimulate choroidal neovascularization (CNV), characteristic of “wet” AMD. PPAR-α is found in retina and also on vascular cells important to formation of CNV. At this time, however, relatively little is known about potential contributions of PPAR-α to the pathogenesis of dry and wet AMD. This review examines current literature for potential roles of PPAR-α in the pathogenesis and potential treatment of AMD with emphasis on prevention and treatment of wet AMD.

Copyright © 2008 M. del V Cano and P. L. Gehlbach. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

Age-related macular degeneration (AMD) is the leading cause of new blindness in the Western World and is currently responsible for more than half of all legal blindness in the United States. There are approximately 8 million people in the U.S. with early or intermediate stage AMD. Approximately one million of these people will develop advanced disease within the next five years [1–5]. Currently AMD is estimated to affect about 50 million people worldwide. With aging of the population this number is expected to double by the year 2020. Strategic approaches to management of AMD include delaying onset and progression of nonneovascular “(dry)” disease; preventing conversion from dry to wet disease and treatment of wet disease.

While specific antioxidant vitamin formulations are now known to delay progression of intermediate disease, current treatment of AMD focuses largely on providing therapeutic intervention following the progression of intermediate “(dry)” disease to late stage “(wet)” disease. The neovascular (“wet” or “exudative”) form of AMD can lead to rapid visual decline and accounts for nearly 90% of vision lost. It is characterized by development of pathologic choroidal neovascularization (CNV). Early strategies to ablate CNV used thermal laser or photodynamic therapy. These are now less frequently used as treatments that antagonize the effects of vascular endothelial growth factor (VEGF), continue to enhance efficacy, and improve outcomes. Currently pegaptanib, ranibizumab, and bevacizumab are considered relatively safe and achieve therapeutic effects that may include inhibition/regression of CNV, decreased vascular leakage, absorption of subretinal fluid, and improved vision [6–10].

The peroxisome proliferator-activated receptors (PPAR’s) are not, at the present time, known as direct treatment targets in the management of AMD. Each represents a separate nuclear receptor of the steroid super-family of ligand activated transcription factors that induce steroid hormones, thyroid hormones, vitamin D, and retinoid acid receptor [11]. PPAR’s comprise a family of three ligand-activated transcription factors (α, β, and γ) that are characterized by distinct function, ligand specificity, and tissue distribution. The PPAR transcription factors regulate transcription of many genes involved in differentiation, proliferation, and apoptosis, in a variety of cell types. During gene expression the PPAR forms a heterodimer receptor complex with the 9-cis-retinoic acid receptor (RXR). The PPAR/RXR
heterodimer is associated with a multiprotein corepressor. When a ligand or agonist binds to the receptor, the corepressor complex dissociates. The heterodimer receptor then binds with peroxisome proliferator response elements on the promoter domain of target genes to stimulate transcription [12].

Three distinct PPAR's had been identified in mammals, PPAR-α, PPAR-γ, and PPAR-β (also referred to as PPAR-δ). The first PPAR entity identified was PPAR-α agonist, which has multiple functions that result in an improved lipid profile, increasing high density lipoprotein cholesterol (HDL-C), decreasing triglycerides and free fatty acids, and shifting low density lipoprotein cholesterol (LDL-C) to larger less atherogenic particles. Each of these improvements in the lipid profile is potentially beneficial and may in theory lead to delay in AMD onset and progression thereby avoiding late stage or “wet” disease.

PPAR-α is transcribed from chromosome 22q12-13.1, is primarily expressed in tissues with elevated mitochondrial and peroxisomal fatty acids β-oxidation rates, such as liver, heart muscle, kidney, skeletal muscle, retina, and brown fat [13–15] and may have a potential role in oxidant/antioxidant pathways now strongly implicated in the pathogenesis of dry AMD. PPAR-α is also present in cells of the arterial wall associated with smooth muscle cells [16] and endothelial cells [17] and is found in monocytes and macrophages [18] that participate in CNV formation, characteristic of wet AMD [19]. The PPAR's are activated by a number of ligands including eicosanoids and fatty acids. In addition, synthetic antidiabetic and lipid lowering fibrates have been shown to activate PPAR-γ and PPAR-α, respectively. PPAR-α is the main target of fibrate drugs, a class of amphipathic carboxylic acids (gemfibrozil, fenofibrate, clofibrate) used in managing elevated triglycerides and cholesterol. PPAR-γ is highly expressed in adipose tissues and is a key mediator of adipogenesis [20, 21] and glucose homeostasis [22]. Little is known about the PPAR-δ which is expressed ubiquitously and has now been linked to obesity.

2. PPARs IN THE VASCULATURE

In addition to well established roles for the PPAR’s in metabolic pathways, recent work suggests that the PPAR’s may be involved in vascular regulation. Several groups have identified PPAR-γ and PPAR-α expression in monocytes/macrophages, vascular smooth muscle cells, and endothelial cells [16–18]. In the endothelium, PPAR-γ has been identified by PCR reaction [23], western blot and immunoprecipitation. PPAR-α has been demonstrated in the vascular endothelium by immunohistochemical technique [24]. While PPAR-γ has been widely studied for its antiangiogenic properties [25], recent studies now indicate that PPAR-α may have antiangiogenic properties as well [26, 27], a finding with potential therapeutic implications for wet AMD. PPAR-α agonists have recently been shown to inhibit expression of VEGF receptor 2 (VEGFR2) upregulation in neovascularization [26]. Varet et al. have demonstrated that fenofibrate, a PPAR-α ligand, inhibits angiogenesis in vitro and in vivo. They have also shown that fenofibrate reduces endothelial cell growth rate, endothelial cell mediated wound repair, and capillary tube formation. Interestingly fenofibrate has been shown to inhibit bFGF-induced angiogenesis in vivo [27]. Simultaneous inhibition of VEGFR2, bFGF, and VEGF would in theory have a profound effect on pathological angiogenesis in the eye.

PPAR-α and PPAR-γ are associated with anti-inflammatory and antioxidant activity [28–30] and have antiatherogenic effects [31]. Each of these pathways is considered important to the onset and progression of early AMD and to development of late choroidal neovascularization. PPAR-α activators inhibit expression of vascular adhesion molecules on the endothelium that are important for the development of new blood vessels and for atherogenesis [32]. Experimental evidence suggests that the PPAR activators prevent in vitro vascular muscle cell growth [33], limit inflammatory responses [16], and are proapoptotic indicating a potential role in vascular remodeling [34]. Such activity could theoretically inhibit the transition from dry to wet AMD. PPAR-α agonists also inhibit interleukin-1-induced production of interleukin-6 and prostaglandins [16]. Moreover, Delerive et al. have demonstrated prolonged inflammatory responses and increased interleukin-6 production in aortic explants of PPAR-α deficient mice [35] underscoring the anti-inflammatory potential of PPAR-α.

3. PPAR-α IN ANGIOGENESIS

Pathological angiogenesis leading to choroidal neovascularization is pathognomonic of “wet” AMD. Angiogenesis is the formation of new blood vessels from preexisting vessels and involves endothelial cell proliferation, migration, and organization into new capillary tubes. Pathological angiogenesis is integral to a number of prevalent ocular diseases characterized by the development of ocular neovascularization including but not limited to wet AMD, diabetic retinopathy, corneal neovascularization, the occlusive retinal vasculopathies, and retinopathy of prematurity. Inhibitors of ocular angiogenesis therefore have broad therapeutic implications for patients with these diseases.

Varet et al. demonstrated inhibition of angiogenesis by the PPAR-α ligand fenofibrate [27]. The antiangiogenic properties exhibited were characterized by a dose-dependent decrease in endothelial cell proliferation and apoptosis. Fenofibrates also reduced endothelial cell migration in vitro and capillary tube formation in a matrigel assay. Meissner et al. have also reported a reduction in endothelial cell proliferation, migration, and tube formation following treatment with fenofibrates and also with the PPAR-α agonist Wy14643 [26]. In further support of the evident antiangiogenic effect is the observation that several PPAR-α agonists decrease expression of VEGF receptor 2 (VEGFR2) in human umbilical endothelial cells (HUVECs) [26].

VEGFR2 is the most potent of the VEGF receptors. When activated VEGFR2 initiates signaling that leads to endothelial cell proliferation and also to expression of cytoprotective antiapoptotic molecules [36]. VEGFR2 is detectable only at relatively low levels in the adult vasculature; it is markedly up regulated by blood vessels during chronic inflammation,
hypoxia, tumor growth, and wound repair. VEGFR2 and VEGF expression both increase as part of the angiogenic response and this coordinate response is observed in wet AMD as well as other ocular diseases characterized by pathological neovascularization [37, 38]. VEGF has been identified in fibroblastic cells and transfused differentiated RPE cells in surgically excised choroidal neovascular membranes (CNV) [39, 40]. VEGF expression is also increased in macular RPE cells in patients with AMD [41]. Vitreous VEGF levels are significantly higher in AMD patients with CNV as compared to healthy controls [42]. VEGF production is also increased in RPE cells, retinal vascular endothelial cells, retinal pericytes [43–45], and Muller cells [46]. The endothelial cells of the retinal vasculature possess numerous high-affinity VEGF receptors.

PPAR-α agonists have been associated with a reduction in VEGF levels in OVCAR-3 tumor as well as in DISS-derived ascites [47]. They also reduce microvessel density in these tumors. Other studies have similarly demonstrated that a reduction in PPAR-α message and activity is associated with hypoxia [48]. Hypoxia-induced VEGF expression contributes to choroidal and retinal neovascularization. The relative significance of the effect of PPAR-α on VEGF and VEGF expression in the setting of AMD is not yet known.

4. PPAR-α AND WET AMD

Fenofibrates and other PPAR-α agonists are reported to decrease expression of VEGF and VEGF2 that are central to the VEGF/VEGFR signaling cascade and important to the development of pathological CNV in AMD. Growth of experimentally induced CNV, via laser rupture of Bruch's membrane in a rat model, is inhibited by intravitreous treatment with a PPAR-γ agonist [49]. At the time of this writing, similar data has not been reported for PPAR-α. Evaluation of this question is however supported by evidence of PPAR-α reduction of VEGFR2 expression in endothelial cells [26] and reported decreases in tissue VEGF levels [47]. PPAR-α activators have also been shown to limit the expression of vascular cell adhesion molecules in the endothelium, an early step in atherogenesis and an important step in the development of new blood vessels [32]. Inhibition of CNV initiation and early progression of CNV are therefore theoretical benefits of PPAR-α agonist treatment. Described proapoptotic effects also suggest therapeutic roles in early CNV development or late regression of CNV [34].

With reports that the PPAR's limit inflammatory as well as oxidative responses and improve lipid profiles [16, 28, 29, 35, 37, 50], it is tempting to speculate on a potential role in delaying onset and progression of nonneovascular "(dry)" disease, thereby potentially preventing latter "wet" stages of disease. There is a substantial literature linking oxidative damage to dry AMD pathogenesis [51]. PPAR-α could theoretically inhibit AMD progression via effects on oxidative pathways. It has been previously reported that PPAR-α activation induces the expression and activation of antioxidant enzymes, such as super oxide dismutase and glutathione peroxidase [29]. It has also been reported that PPAR-α agonists are neuroprotective in the CNS, and that this neuroprotection has been associated with a decrease in cerebral oxidative stress. Consumption of direct acting antioxidants to provide protection to the retina and the RPE is supported by the AREDS clinical trial that added antioxidant formulation to the routine care of dry AMD. Whether the antioxidant effects of PPAR-α activation are comparable to those of AREDS formulation is not known.

Because fenofibrates are orally administered and have an established safety profile in the treatment of atherosclerosis, investigations pertaining to the impact of oral therapy on oxidative stress, VEGFR2, VEGF, and CNV growth are important. It is also important to consider examining for potential beneficial effects on onset and progression of nonneovascular "(dry)" disease and conversion from dry to wet disease. These and other factors support a hypothesis that asks whether PPAR-α may play a therapeutic role in either prevention or treatment of wet AMD.

5. SUMMARY

AMD remains the leading cause of new blindness in people over 65 years of age and is the leading cause of new blindness in the Western World. The conversion of dry AMD to wet AMD is associated with most of the attendant visual decline. Currently a variety of antiangiogenic treatments directed at halting CNV growth and leakage are the mainstay of therapy. The most frequently injected agent ranibizumab (Lucentis) results in stabilization of visual acuity at the pretreatment level for a majority of patients and results in improvement of visual acuity by 3 or more lines in about 1/3 of those treated. The therapy does not however restore visual acuity to normal levels in the majority of those treated. Moreover, therapy with ranibizumab and other currently available VEGF antagonists requires frequent intravitreous injections and is associated with significant expense, some risk, and for most, incomplete recovery of vision.

An oral therapy with an established safety profile that favorably modified VEGF/VEGFR signaling and increased the antioxidant capacity could significantly impact the therapy of wet AMD. Taken collectively, the PPAR's demonstrate favorable biological activity in pathophysiological pathways relevant to the onset and progression of nonneovascular and neovascular age-related macular degeneration. The relative importance of the PPAR-α pathway in AMD is not yet known. There is, however, sufficient preliminary evidence to support further study of a potential role for PPAR-α pathway modulation as an adjuvant or primary treatment in AMD.

ACKNOWLEDGMENTS

This work is financially supported by the JG Foundation (PLG); an unrestricted grant from Research to Prevent Blindness (Wilmer Eye Institute) and a Research to Prevent Blindness Career Development Award (PLG); William Weis Award (PLG); Jack and Gail Baylin Philanthropic Fund; the JHU Fund for Medical Discovery (PLG) and a gift from Kenneth and Brenda Richardson (PLG).
REFERENCES

[1] R. Klein, B. E. Klein, and K. L. Linton, “Prevalence of age-related maculopathy. The Beaver Dam Eye Study,” Ophthalmology, vol. 99, no. 6, pp. 933–943, 1992.

[2] F. Kinoste, G. Roscilli, S. Lamartina, et al., “Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor,” Molecular Vision, vol. 11, pp. 366–373, 2005.

[3] B. Muñoz, S. K. West, G. S. Rubin, et al., “Causes of blindness and visual impairment in a population of older Americans. The Salisbury Eye Evaluation Study,” Archives of Ophthalmology, vol. 118, no. 6, pp. 819–825, 2000.

[4] R. Klein, B. E. Klein, S. C. Jensen, and S. M. Meuer, “The five-year incidence and progression of age-related maculopathy. The Beaver Dam Eye Study,” Ophthalmology, vol. 104, no. 1, pp. 7–21, 1997.

[5] H. M. Leibowitz, D. E. Krueger, L. R. Maunder, et al., “The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973–1975,” Survey of Ophthalmology, vol. 24, supplement 1, pp. 335–610, 1980.

[6] E. W. M. Ng, D. T. Shima, P. Calias, E. T. Cunningham Jr., D. R. Geyer, and A. P. Adams, “Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease,” Nature Reviews Drug Discovery, vol. 5, no. 2, pp. 123–132, 2006.

[7] J. S. Heier, A. N. Antoszyk, P. R. Pavan, et al., “Ranibizumab for treatment of neovascular age-related macular degeneration. A phase I/Ii multicenter, controlled, multidose study,” Ophthalmology, vol. 113, no. 4, pp. 633–642, 2006.

[8] S. Michels and P. J. Rosenfeld, “Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucantis,” Klinische Monatsblätter für Augenheilkunde, vol. 222, no. 6, pp. 480–484, 2005.

[9] S. Michels, P. J. Rosenfeld, C. A. Pullafito, E. N. Marcus, and A. S. Venkatraman, “Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study,” Ophthalmology, vol. 112, no. 6, pp. 1035–1047, 2005.

[10] R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006.

[11] C. Bonne, “PPAR γ: a novel pharmacological target against retinal and choroidal neovascularization,” Journal Français d’Ophthalmologie, vol. 28, no. 3, pp. 326–330, 2005.

[12] F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O’Connell, “Evolusion of peroxisome proliferator-activated receptor agonists,” The Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007.

[13] O. Braissant, F. Foufelle, C. Scotto, M. Daucu, and W. Wahl, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, β, and γ in the adult rat,” Endocrinology, vol. 137, no. 1, pp. 354–366, 1996.

[14] D. Auboeuf, J. Rieuze, L. Fajas, et al., “Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients,” Diabetes, vol. 46, no. 8, pp. 1319–1327, 1997.

[15] T. Lemberger, O. Braissant, C. Juge-Aubry, et al., “PPAR tissue distribution and interactions with other hormone-signaling pathways,” The Annals of the New York Academy of Sciences, vol. 804, pp. 231–251, 1996.

[16] B. Staels, W. Koenig, A. Habib, et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998.

[17] I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998.

[18] G. Chinetti, S. Griglio, M. Antonucci, et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998.

[19] S. W. Cousins, D. G. Espinosa-Heidmann, and K. G. Caaky, “Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization?” Archives of Ophthalmology, vol. 122, no. 7, pp. 1013–1018, 2004.

[20] A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation,” Endocrinology, vol. 135, no. 2, pp. 798–800, 1994.

[21] J. Auwerx, G. Martin, M. Guerre-Millo, and B. Staels, “Transcription, adipocyte differentiation, and obesity,” Journal of Molecular Medicine, vol. 74, no. 7, pp. 347–352, 1996.

[22] R. Komers and A. Vrana, “Thiazolidinediones—tools for the research of metabolic syndrome X,” Physiological Research, vol. 47, no. 4, pp. 215–225, 1998.

[23] H. Itoh, K. Doi, T. Tanaka, et al., “Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor γ,” Clinical and Experimental Pharmacology and Physiology, vol. 26, no. 7, pp. 558–560, 1999.

[24] J. Plutzky, “Peroxisome proliferator-activated receptors in endothelial cell biology,” Current Opinion in Lipidology, vol. 12, no. 5, pp. 511–518, 2001.

[25] C. Giaginis, A. Margeli, and S. Theocharis, “Peroxisome proliferator-activated receptor-γ ligands as investigational modulators of angiogenesis,” Expert Opinion on Investigational Drugs, vol. 16, no. 10, pp. 1561–1572, 2007.

[26] M. Meissner, M. Stein, C. Urbich, et al., “PPARα activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation,” Circulation Research, vol. 94, no. 3, pp. 324–332, 2004.

[27] J. Varet, L. Vincent, P. Mirshahi, et al., “Fenofibrate inhibits angiogenesis in vitro and in vivo,” Cellular and Molecular Life Sciences, vol. 60, no. 4, pp. 810–819, 2003.

[28] X. R. Chen, V. C. Besson, B. Palmer, Y. Garcia, M. Plotkine, and C. Marchand-Leroux, “Neurological recovery-promoting, fenofibrate, a PPAR γ ligand, and C. Marchand-Leroux, “Neurological recovery-promoting,” Circulation Research, vol. 94, no. 3, pp. 324–332, 2004.

[29] S. Han, M. J. Quon, and K. K. Koh, “Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptors,” Diabetes, vol. 44, no. 3, pp. 698–705, 2005.
receptor-α activators,” *Hypertension*, vol. 46, no. 5, pp. 1086–1092, 2005.

[32] Z. Israeli-Konaraki and P. D. Reaven, “Peroxisome proliferator-activated receptor-α and atherosclerosis: from basic mechanisms to clinical implications,” *Cardiology*, vol. 103, no. 1, pp. 1–9, 2005.

[33] N. Marx, U. Schönbeck, M. A. Lazar, P. Libby, and J. Plutzky, “Peroxisome proliferator-activated receptor γ activators inhibit gene expression and migration in human vascular smooth muscle cells,” *Circulation Research*, vol. 83, no. 11, pp. 1097–1103, 1998.

[34] M. Iglarz, R. M. Touyz, F. Amiri, M.-F. Lavoie, Q. N. Diep, and E. L. Schiffrin, “Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 23, no. 1, pp. 45–51, 2003.

[35] P. Delerive, J. C. Fruchart, and B. Staels, “Peroxisome proliferator-activated receptors in inflammation control,” *Journal of Endocrinology*, vol. 169, no. 3, pp. 453–459, 2001.

[36] N. Ferrara and H.-P. Gerber, “The role of vascular endothelial growth factor in angiogenesis,” *Acta Haematologica*, vol. 106, no. 4, pp. 148–156, 2001.

[37] A. D. Kulkarni and B. D. Kuppermann, “Wet age-related macular degeneration,” *Advanced Drug Delivery Reviews*, vol. 57, no. 14, pp. 1994–2009, 2005.

[38] N. Ferrara, “The role of VEGF in the regulation of physiological and pathological angiogenesis,” *EXS*, no. 94, pp. 209–231, 2005.

[39] A. Kvant, P. V. Algvere, L. Berglin, and S. Seregard, “Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor,” *Investigative Ophthalmology and Visual Science*, vol. 37, no. 9, pp. 1929–1934, 1996.

[40] P. F. Lopez, B. D. Sippy, H. M. Lambert, A. B. Thach, and D. R. Hinton, “Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes,” *Investigative Ophthalmology and Visual Science*, vol. 37, no. 5, pp. 855–868, 1996.

[41] M. Kliffen, H. S. Sharma, C. M. Mooy, S. Kerkvliet, and P. T. de Jong, “Increased expression of angiogenic growth factors in age-related maculopathy,” *British Journal of Ophthalmology*, vol. 81, no. 2, pp. 154–162, 1997.

[42] J. A. Wells, R. Murthy, R. Chibber, et al., “Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation,” *British Journal of Ophthalmology*, vol. 80, no. 4, pp. 363–366, 1996.

[43] V. Simonne-Pinatel, M. Guerrin, P. Chollet, et al., “Vasculotropin-VEGF stimulates retinal capillary endothelial cells through an autocrine pathway,” *Investigative Ophthalmology and Visual Science*, vol. 35, no. 9, pp. 3393–3400, 1994.

[44] L. P. Aiello, J. M. Northrup, B. A. Keyt, H. Takagi, and M. A. Iwamoto, “Hypoxic regulation of vascular endothelial growth factor in retinal cells,” * Archives of Ophthalmology*, vol. 113, no. 12, pp. 1538–1544, 1995.

[45] A. P. Adams, D. T. Shima, K. T. Yeo, et al., “Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells,” *Biochemical and Biophysical Research Communications*, vol. 193, no. 2, pp. 631–638, 1993.

[46] E. A. Pierce, R. L. Avery, E. D. Foley, L. P. Aiello, and L. E. H. Smith, “Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascu-